CervoMed 8-K: Material Agreement & Officer Changes on Feb 1

TL;DR

**CervoMed just announced a material agreement and officer changes, big news for its future direction.**

AI Summary

CervoMed Inc. filed an 8-K on February 2, 2024, reporting events from February 1, 2024, related to an entry into a material definitive agreement and changes in directors or officers. This filing indicates significant corporate actions, potentially impacting the company's strategic direction or financial structure. Investors should pay close attention to the details of these agreements and personnel changes, as they could signal future growth opportunities or operational challenges for CervoMed Inc.

Why It Matters

This filing signals potential shifts in CervoMed's business strategy or leadership, which could influence its future performance and stock valuation.

Risk Assessment

Risk Level: medium — The filing indicates material definitive agreements and officer changes, which can introduce both opportunities and risks depending on the specifics not detailed in this summary.

Analyst Insight

Investors should seek out the full details of the 'Material Definitive Agreement' and the 'Departure of Directors or Certain Officers' mentioned in this 8-K to understand the specific implications for CervoMed Inc.'s future operations and financial health before making any investment decisions.

Key Players & Entities

• CervoMed Inc. (company) — the registrant filing the 8-K
• February 1, 2024 (date) — date of the earliest event reported
• February 2, 2024 (date) — date the 8-K was filed
• 001-37942 (other) — Commission File Number
• 30-0645032 (other) — I.R.S. Employer Identification No.
• Delaware (other) — State of incorporation for CervoMed Inc.
• 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 (other) — Address of principal executive offices for CervoMed Inc.
• (617) 744-4400 (other) — Registrant’s telephone number

FAQ

Key Financial Figures

• $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market
• $538,534 — eceive an initial annual base salary of $538,534.86, and has an initial target bonus opp
• $465,750 — eceive an initial annual base salary of $465,750.00, and has an initial target bonus opp
• $316,549 — eceive an initial annual base salary of $316,549.78, and has an initial target bonus opp

Filing Documents

• crvo20240126_8k.htm (8-K) — 36KB
• ex_619845.htm (EX-10.1) — 113KB
• ex_619846.htm (EX-10.2) — 117KB
• ex_619847.htm (EX-10.3) — 110KB
• 0001437749-24-002955.txt ( ) — 591KB
• crvo-20240201.xsd (EX-101.SCH) — 3KB
• crvo-20240201_def.xml (EX-101.DEF) — 11KB
• crvo-20240201_lab.xml (EX-101.LAB) — 15KB
• crvo-20240201_pre.xml (EX-101.PRE) — 11KB
• crvo20240126_8k_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. The information provided in Item 5.02 of this current report on Form 8-K is incorporated by reference into this Item 1.01 to the extent applicable. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On February 1, 2024, CervoMed Inc. (the "Company") entered into employment agreements (each, an "Employment Agreement") with each of John Alam, M.D., the Company's President and Chief Executive Officer, Robert J. Cobuzzi, Jr., Ph.D., the Company's Chief Operating Officer, and Kelly Blackburn, M.H.A., the Company's Senior Vice President, Clinical Development. Dr. Alam's Employment Agreement supersedes the terms of his prior employment agreement, dated April 2, 2018, with EIP Pharma, Inc., the Company's wholly-owned subsidiary ("EIP"), Dr. Cobuzzi's Employment Agreement supersedes the terms of his prior employment agreement, dated September 8, 2020, as amended March 29, 2023, with the Company, and Ms. Blackburn's Employment Agreement supersedes the terms of her prior offer letter, dated April 29, 2018, as amended January 29, 2019, with EIP. Compensation and Other Benefits Pursuant and subject to the terms and conditions of their respective Employment Agreements: (i) Dr. Alam will continue to serve as the Company's Chief Executive Officer, receive an initial annual base salary of $538,534.86, and has an initial target bonus opportunity equal to 50% of his base salary; (ii) Dr. Cobuzzi will continue to serve as the Company's Chief Operating Officer, receive an initial annual base salary of $465,750.00, and has an initial target bonus opportunity equal to 50% of his base salary; and (iii) Ms. Blackburn will continue to serve as the Company's Senior Vice President, Clinical Development, receive an initial annual base salary of $316,549.78, and has an initial target bonus opportunity equal to 35% of her base

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Amended & Restated Employment Agreement, dated February 1, 2024, by and between CervoMed Inc. and John Alam, M.D. 10.2 Amended & Restated Employment Agreement, dated February 1, 2024, by and between CervoMed Inc. and Robert J. Cobuzzi, Jr., Ph.D. 10.3 Employment Agreement, dated February 1, 2024, by and between CervoMed Inc. and Kelly Blackburn, M.H.A. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 2, 2024 CervoMed Inc. By: /s/ William Elder __________ Name: William Elder Title: General Counsel 4

View Full Filing

View this 8-K filing on SEC EDGAR